Ajinomoto AminoScience

Ajinomoto AminoScience is a global leader in the research, development, and manufacturing of pharmaceutical-grade amino acids and a premier Contract Development and Manufacturing Organization (CDMO). As a core division of the Ajinomoto Group, the company leverages over a century of expertise in 'AminoScience' to provide high-purity ingredients for the pharmaceutical, biotech, and nutraceutical industries. Its service portfolio includes advanced protein expression systems like CORYNEX, liquid-phase peptide and oligonucleotide synthesis via AJIPHASE, and site-specific antibody-drug conjugation through AJICAP. Following the acquisition of Forge Biologics, the company has significantly expanded its capabilities into gene therapy manufacturing and development. Ajinomoto AminoScience operates major cGMP facilities in the United States, Japan, and Europe, supporting clients from early-stage R&D through commercial-scale production.